Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Inclusion Criteria:

1. Adult females or males age ≥ 40 years
2. Ability to read and speak English

Exclusion Criteria:

1. Current use of a dietary supplement containing fulvic or humic acid
2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
3. Known allergies to any ingredients in the product
4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
6. Participants unable to provide consent